Zydus Lifesciences has reported results for fourth quarter (Q4) and year ended March 31, 2024.
The company has reported over 2- fold jump in its net profit at Rs 1405.20 crore for the quarter under review as compared to Rs 490.70 crore for the same quarter in the previous year. Total income of the company increased by 30.49% at Rs 3693.50 crore for Q4FY24 as compared Rs 2830.50 crore for the corresponding quarter previous year.
On consolidated basis, the company has reported 3- fold jump in its net profit at Rs 1182.30 crore for fourth quarter ended March 31, 2024 as compared to Rs 296.60 crore for the same quarter in the previous year. Total income of the company increased by 12.71% at Rs 5690.20 crore for Q4FY24 as compared Rs 5048.40 crore for the corresponding quarter previous year.
For the year ended March 31, 2024, the company has reported over 2- fold jump in its net profit at Rs 3441.50 crore as compared to Rs 1529.20 crore for the previous year. Total income of the company increased by 28.27% at Rs 11903.50 crore for year under review as compared to Rs 9280.00 crore for year ended March 31, 2023.
For the year ended March 31, 2024, on the consolidated basis, the company has reported 96.88% rise in its net profit at Rs 3859.50 crore as compared to Rs 1960.30 crore for the previous year. Total income of the company increased by 13.81% at Rs 19831.50 crore for year under review as compared to Rs 17424.00 crore for year ended March 31, 2023.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1453.25 |
Dr. Reddys Lab | 5792.95 |
Cipla | 1459.85 |
Zydus Lifesciences | 1032.25 |
Lupin | 1583.95 |
View more.. |